Washington-based Chase Pharmaceuticals has appointed Douglas Ingram as its new chief executive officer to replace John Siebert, who will continue working with the company in an advisory capacity. Mr. Ingram brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership. Prior to serving as president of Allergan, Ingram directed the company’s operations in Europe, the Middle East and Africa and was responsible for various aspects of its global ...